PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

King’s College London explore COVID-19 technology as heart attack cure

Protein technology could dramatically improve the prospects for heart attack victims by proliferating organ cells

A public research university, King’s College London, is utilising messenger RNA (mRNA) technology to combat the physiological effects of heart attacks, in an effort to develop the world’s first cure for heart attack victims. The technology has the potential for a near reversal of heart damage.

mRNAs are genetic codes that produce proteins that contain genetic information. The mRNA technology being used by King’s College university produces proteins stimulating the creation of healthy new heart cells and can be delivered directly to the heart muscle following an attack.

The proteins which are created through the technology can assist the heart muscle in the regeneration of cells. This ground-breaking response has not yet been incorporated into any cardiac medications or post-episode treatments.

Mauro Giacca, Professor of cardiovascular sciences at the School of Cardiovascular Medicine and Sciences, King’s College, explained: “We are all born with a set number of muscle cells in our heart and they are exactly the same ones we will die with. Our goal has been to find a treatment that can convince surviving cells to proliferate.”

“We are using exactly the same technology as the Pfizer and Moderna vaccines to inject micro RNAs to the heart, reaching surviving heart cells and pushing their proliferation,” he added.

If the technology advances to regulatory approval with indications for heart attack patients, the standard of cardiac care could be drastically improved, and the lives of millions worldwide could be extended.

The research has also identified proteins that could be injected into heart attack patients in the back of an ambulance to prevent heart cells from dying.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026